FTC again charges Endo and Impax of blocking competition in US oxymorphone ER market

26 January 2021

The US Federal Trade Commission (FTC) yesterday filed a new antitrust complaint accusing Endo Pharmaceuticals (Nasdaq: ENDP) and Impax Laboratories, as well as the latter’s owner, Amneal Pharmaceuticals (NYSE: AMRX), of striking a second deal to stave off competition to the Opana ER (oxymorphone hydrochloride extended release) opioid pain medication even as an earlier FTC enforcement action over the same drug was moving forward.

The FTC sued Endo and max in January 2017 for engaging in similar anticompetitive conduct concerning the same drug product.

Amneal’s shares closed down 2.4% to $4.85 yesterday and declined a further 1% after hours, while Endo rose more than 5%, but fell back 2.3% pre-market today to $7.11.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK